Brief: Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For Cdi At The 16Th Biennial Congress Of The Anaerobe Society Of America
02/08/2022 14:13
Aug 2 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES NEW DATA PRESENTATIONS FROM ONGOING PH2
CLINICAL
TRIAL PROGRAM OF IBEZAPOLSTAT FOR CDI AT THE 16TH BIENNIAL
CONGRESS OF THE ANAEROBE SOCIETY OF AMERICA
Source text for Eikon: ID:nPn1YQn3Sa
Further company coverage: ACXP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program